Read more

October 17, 2024
36 min listen
Save

Advocating for Patient Access with Amita Patnaik, MD, FRCPC

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this episode, host Shikha Jain, MD, speaks with Amita Patnaik, MD, FRCPC, about providing patient access to breakthrough drug developments, bringing early phase cancer trials to physicians and more.

  • Welcome to another exciting episode of Oncology Overdrive 0:14
  • About Patnaik 0:21
  • The interview 1:23
  • How did you decide to become an oncologist, and how did you end up co-founding the START Center for Cancer Research? 1:32
  • Can you tell me about START’s overarching purpose and where you see its need being most fulfilled? […] What do you hope START will accomplish in the next five to ten years? 11:33
  • How successful has START been at including underrepresented patient populations in clinical data? 17:52
  • What are some challenges you’ve found as you have navigated through founding a company and executing its mission? 21:48
  • What is next for you?25:21
  • If someone else wanted to create a company like START, what are some tips you would give them?27:23
  • If someone could only listen to the last few minutes of this episode, what would you want them to take away? 32:03
  • How to contact Patnaik 34:44
  • Thanks for listening 35:27

Amita Patnaik, MD, FRCPC, is an internationally recognized medical oncologist and the co-founder of the START Center for Cancer Research.

We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Patnaik can be reached via email amita.patnaik@startresearch.com or via the START website.

Sources/Disclosures

Collapse

Disclosures: Jain and Patnaik report no relevant financial disclosures.